Centiva Capital’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.48M Buy
10,600
+600
+6% +$84K 0.01% 501
2025
Q4
$1.23M Buy
+10,000
New +$1.22M 0.01% 522
2025
Q1
Sell
-5,700
Closed -$527K 1756
2024
Q4
$527K Sell
5,700
-10,000
-64% -$900K 0.01% 793
2024
Q3
$1.32M Buy
15,700
+10,000
+175% +$763K 0.03% 688
2024
Q2
$391K Hold
5,700
0.01% 1311
2024
Q1
$418K Sell
5,700
-4,300
-43% -$331K 0.01% 1081
2023
Q4
$810K Sell
10,000
-6,100
-38% -$475K 0.02% 713
2023
Q3
$1.21M Buy
16,100
+6,100
+61% +$469K 0.03% 549
2023
Q2
$771K Sell
10,000
-10,000
-50% -$798K 0.02% 661
2023
Q1
$1.66M Sell
20,000
-30,000
-60% -$2.48M 0.04% 461
2022
Q4
$4.29M Hold
50,000
0.12% 178
2022
Q3
$3.08M Sell
50,000
-200
-0.4% -$12.6K 0.06% 247
2022
Q2
$3.1M Sell
50,200
-19,500
-28% -$1.21M 0.07% 240
2022
Q1
$4.14M Sell
69,700
-121,200
-63% -$7.75M 0.08% 217
2021
Q4
$13.9M Buy
190,900
+190,230
+28,393% +$13.1M 0.29% 61
2021
Q3
$47K Sell
670
-29,330
-98% -$2.06M ﹤0.01% 1133
2021
Q2
$2.07M Buy
+30,000
New +$2M 0.05% 316
2021
Q1
Sell
-8,300
Closed -$483K 1242
2020
Q4
$483K Sell
8,300
-13,100
-61% -$790K 0.02% 472
2020
Q3
$1.35M Buy
21,400
+8,800
+70% +$610K 0.09% 160
2020
Q2
$969K Buy
12,600
+5,800
+85% +$444K 0.06% 182
2020
Q1
$508K Sell
6,800
-97,800
-93% -$6.76M 0.02% 308
2019
Q4
$6.8M Buy
104,600
+55,200
+112% +$3.59M 0.33% 63
2019
Q3
$3.13M Buy
49,400
+7,100
+17% +$464K 0.19% 107
2019
Q2
$2.86M Sell
42,300
-46,800
-53% -$3.08M 0.17% 110
2019
Q1
$5.79M Buy
89,100
+11,700
+15% +$778K 0.39% 39
2018
Q4
$4.84M Buy
77,400
+3,000
+4% +$210K 0.38% 45
2018
Q3
$5.75M Buy
+74,400
New +$5.62M 0.5% 30

Other funds holding GILD

Centiva Capital's GILD Position: Q1 2026 in Review

Centiva Capital reduced its Gilead Sciences (GILD) stake by 6.2% in Q1 2026, selling an estimated $15.3K and leaving 1,652 shares worth $230K. The position accounts for ﹤0.01% of the portfolio, ranked #1204.

Centiva Capital first reported a position in GILD in Q1 2018 and has held it in 26 quarters since. The position peaked at $6.01M in Q1 2023. 2,311 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Centiva Capital held 1,652 shares of Gilead Sciences worth $230K as of Q1 2026.
  • Centiva Capital sold 109 Gilead Sciences shares in Q1 2026, an estimated $15.3K.
  • Gilead Sciences made up ﹤0.01% of Centiva Capital's portfolio in Q1 2026, its #1204 holding.
  • Centiva Capital first reported a position in Gilead Sciences in Q1 2018 and has held it in 26 quarters since.
  • Centiva Capital's Gilead Sciences position peaked at $6.01M in Q1 2023.
  • 2,311 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Centiva Capital's 13F filing for Q1 2026, filed 14 May 2026.